Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 242

1.

Seasonal viral influenza among persons with primary antibody immunodeficiency.

Ballow M, Henderson T, Scalchunes C, Blaese RM.

J Allergy Clin Immunol Pract. 2019 Mar;7(3):1058-1060.e3. doi: 10.1016/j.jaip.2018.12.002. Epub 2018 Dec 8. No abstract available.

PMID:
30537559
2.

Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts.

Medical Advisory Committee of the Immune Deficiency Foundation, Shearer WT, Fleisher TA, Buckley RH, Ballas Z, Ballow M, Blaese RM, Bonilla FA, Conley ME, Cunningham-Rundles C, Filipovich AH, Fuleihan R, Gelfand EW, Hernandez-Trujillo V, Holland SM, Hong R, Lederman HM, Malech HL, Miles S, Notarangelo LD, Ochs HD, Orange JS, Puck JM, Routes JM, Stiehm ER, Sullivan K, Torgerson T, Winkelstein J.

J Allergy Clin Immunol. 2014 Apr;133(4):961-6. doi: 10.1016/j.jaci.2013.11.043. Epub 2014 Feb 28. Review.

3.

Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans.

Candotti F, Shaw KL, Muul L, Carbonaro D, Sokolic R, Choi C, Schurman SH, Garabedian E, Kesserwan C, Jagadeesh GJ, Fu PY, Gschweng E, Cooper A, Tisdale JF, Weinberg KI, Crooks GM, Kapoor N, Shah A, Abdel-Azim H, Yu XJ, Smogorzewska M, Wayne AS, Rosenblatt HM, Davis CM, Hanson C, Rishi RG, Wang X, Gjertson D, Yang OO, Balamurugan A, Bauer G, Ireland JA, Engel BC, Podsakoff GM, Hershfield MS, Blaese RM, Parkman R, Kohn DB.

Blood. 2012 Nov 1;120(18):3635-46. doi: 10.1182/blood-2012-02-400937. Epub 2012 Sep 11.

4.

Somatic mosaicism in the Wiskott-Aldrich syndrome: molecular and functional characterization of genotypic revertants.

Davis BR, Yan Q, Bui JH, Felix K, Moratto D, Muul LM, Prokopishyn NL, Blaese RM, Candotti F.

Clin Immunol. 2010 Apr;135(1):72-83. doi: 10.1016/j.clim.2009.12.011. Epub 2010 Feb 2.

PMID:
20123155
5.

What is the status of gene therapy for primary immunodeficiency?

Blaese RM.

Immunol Res. 2007;38(1-3):274-84.

PMID:
17917032
6.

Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals.

Morgan RA, Walker R, Carter CS, Natarajan V, Tavel JA, Bechtel C, Herpin B, Muul L, Zheng Z, Jagannatha S, Bunnell BA, Fellowes V, Metcalf JA, Stevens R, Baseler M, Leitman SF, Read EJ, Blaese RM, Lane HC.

Hum Gene Ther. 2005 Sep;16(9):1065-74.

PMID:
16149905
7.

In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.

Okada T, Caplen NJ, Ramsey WJ, Onodera M, Shimazaki K, Nomoto T, Ajalli R, Wildner O, Morris J, Kume A, Hamada H, Blaese RM, Ozawa K.

J Gene Med. 2004 Mar;6(3):288-99.

PMID:
15026990
8.
9.

Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial.

Muul LM, Tuschong LM, Soenen SL, Jagadeesh GJ, Ramsey WJ, Long Z, Carter CS, Garabedian EK, Alleyne M, Brown M, Bernstein W, Schurman SH, Fleisher TA, Leitman SF, Dunbar CE, Blaese RM, Candotti F.

Blood. 2003 Apr 1;101(7):2563-9. Epub 2002 Nov 27.

10.

Immune response to fetal calf serum by two adenosine deaminase-deficient patients after T cell gene therapy.

Tuschong L, Soenen SL, Blaese RM, Candotti F, Muul LM.

Hum Gene Ther. 2002 Sep 1;13(13):1605-10.

PMID:
12228015
11.

A novel approach using transcomplementing adenoviral vectors for gene therapy of adrenocortical cancer.

Wolkersdörfer GW, Bornstein SR, Higginbotham JN, Hiroi N, Vaquero JJ, Green MV, Blaese RM, Aguilera G, Chrousos GP, Ramsey WJ.

Horm Metab Res. 2002 Jun;34(6):279-87. Erratum in: Horm Metab Res. 2002 Oct;34(10):604..

PMID:
12173067
12.
13.

Biosynthetic ganciclovir triphosphate: its isolation and characterization from ganciclovir-treated herpes simplex thymidine kinase-transduced murine cells.

Agbaria R, Candotti F, Kelley JA, Hao Z, Johns DG, Cooney DA, Blaese RM, Ford H Jr.

Biochem Biophys Res Commun. 2001 Nov 30;289(2):525-30.

PMID:
11716505
14.

AV.TK-mediated killing of subcutaneous tumors in situ results in effective immunization against established secondary intracranial tumor deposits.

Okada T, Shah M, Higginbotham JN, Li Q, Wildner O, Walbridge S, Oldfield E, Blaese RM, Ramsey WJ.

Gene Ther. 2001 Sep;8(17):1315-22.

16.

Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection.

Walker RE, Bechtel CM, Natarajan V, Baseler M, Hege KM, Metcalf JA, Stevens R, Hazen A, Blaese RM, Chen CC, Leitman SF, Palensky J, Wittes J, Davey RT Jr, Falloon J, Polis MA, Kovacs JA, Broad DF, Levine BL, Roberts MR, Masur H, Lane HC.

Blood. 2000 Jul 15;96(2):467-74.

17.

Use of a herpes thymidine kinase/neomycin phosphotransferase chimeric gene for metabolic suicide gene transfer.

Candotti F, Agbaria R, Mullen CA, Touraine R, Balzarini J, Johns DG, Blaese RM.

Cancer Gene Ther. 2000 Apr;7(4):574-80.

18.

Human gene marker/therapy clinical protocols.

Rosenberg SA, Blaese RM, Brenner MK, Deisseroth AB, Ledley FD, Lotze MT, Wilson JM, Nabel GJ, Cornetta K, Economou JS, Freeman SM, Riddell SR, Brenner M, Oldfield E, Gansbacher B, Dunbar C, Walker RE, Schuening FG, Roth JA, Crystal RG, Welsh MJ, Culver K, Heslop HE, Simons J, Wilmott RW, Boucher RC, Siegler HF, Barranger JA, Karlsson S, Kohn D, Galpin JE, Raffel C, Hesdorffer C, Ilan J, Cassileth P, O'Shaughnessy J, Kun LE, Das TK, Wong-Staal F, Sobol RE, Haubrich R, Sznol M, Rubin J, Sorcher EJ, Rosenblatt J, Walker R, Brigham K, Vogelzang N, Hersh E, Eck SL.

Hum Gene Ther. 2000 Apr 10;11(6):919-79. No abstract available.

PMID:
10779168
19.

Optimism regarding the use of RNA/DNA hybrids to repair genes at high efficiency.

Blaese RM.

J Gene Med. 1999 Mar-Apr;1(2):144-7. No abstract available.

PMID:
10738578
20.
21.

Human gene marker/therapy clinical protocols.

Rosenberg SA, Blaese RM, Brenner MK, Deisseroth AB, Ledley FD, Lotze MT, Wilson JM, Nabel GJ, Cornetta K, Economou JS, Freeman SM, Riddell SR, Oldfield E, Gansbacher B, Dunbar C, Walker RE, Schuening FG, Roth JA, Crystal RG, Welsh MJ, Culver K, Heslop HE, Simons J, Wilmott RW, Habib NA, et al.

Hum Gene Ther. 1999 Dec 10;10(18):3067-123. No abstract available.

PMID:
10609664
22.
23.

Gene therapy: lessons learnt from the past decade. Interview by Clare Thompson.

Morgan RA, Blaese RM.

BMJ. 1999 Nov 13;319(7220):1310. No abstract available.

25.
26.

Adeno-retroviral chimeric viruses as in vivo transducing agents.

Caplen NJ, Higginbotham JN, Scheel JR, Vahanian N, Yoshida Y, Hamada H, Blaese RM, Ramsey WJ.

Gene Ther. 1999 Mar;6(3):454-9.

27.

Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer.

Wildner O, Morris JC, Vahanian NN, Ford H Jr, Ramsey WJ, Blaese RM.

Gene Ther. 1999 Jan;6(1):57-62.

28.

Retroviral-mediated transfer and expression of the common gamma chain into human hematopoietic progenitors.

Candotti F, Onodera M, Knazek RA, Blaese RM.

Acta Haematol. 1999;101(2):106-10.

PMID:
10202241
29.

Gene therapy for severe combined immunodeficiency caused by adenosine deaminase deficiency: improved retroviral vectors for clinical trials.

Onodera M, Nelson DM, Sakiyama Y, Candotti F, Blaese RM.

Acta Haematol. 1999;101(2):89-96. Review.

PMID:
10202239
30.
31.

The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication.

Touraine RL, Ishii-Morita H, Ramsey WJ, Blaese RM.

Gene Ther. 1998 Dec;5(12):1705-11.

32.
33.
34.

Generation of a conditionally neo(r)-containing retroviral producer cell line: effects of neo(r) on retroviral titer and transgene expression.

Wildner O, Candotti F, Krecko EG, Xanthopoulos KG, Ramsey WJ, Blaese RM.

Gene Ther. 1998 May;5(5):684-91.

35.

Peripheral expansion of pre-existing mature T cells is an important means of CD4+ T-cell regeneration HIV-infected adults.

Walker RE, Carter CS, Muul L, Natarajan V, Herpin BR, Leitman SF, Klein HG, Mullen CA, Metcalf JA, Baseler M, Falloon J, Davey RT Jr, Kovacs JA, Polis MA, Masur H, Blaese RM, Lane HC.

Nat Med. 1998 Jul;4(7):852-6.

PMID:
9662381
36.

T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates.

Kohn DB, Hershfield MS, Carbonaro D, Shigeoka A, Brooks J, Smogorzewska EM, Barsky LW, Chan R, Burotto F, Annett G, Nolta JA, Crooks G, Kapoor N, Elder M, Wara D, Bowen T, Madsen E, Snyder FF, Bastian J, Muul L, Blaese RM, Weinberg K, Parkman R.

Nat Med. 1998 Jul;4(7):775-80.

37.

Gene therapy of primary immunodeficiencies.

Candotti F, Blaese RM.

Springer Semin Immunopathol. 1998;19(4):493-508. Review. No abstract available.

PMID:
9618770
38.

Adenovirus vectors as transcomplementing templates for the production of replication defective retroviral vectors.

Ramsey WJ, Caplen NJ, Li Q, Higginbotham JN, Shah M, Blaese RM.

Biochem Biophys Res Commun. 1998 May 29;246(3):912-9.

PMID:
9618311
39.

Efficient directional cloning of recombinant adenovirus vectors using DNA-protein complex.

Okada T, Ramsey WJ, Munir J, Wildner O, Blaese RM.

Nucleic Acids Res. 1998 Apr 15;26(8):1947-50.

40.

Development of improved adenosine deaminase retroviral vectors.

Onodera M, Nelson DM, Yachie A, Jagadeesh GJ, Bunnell BA, Morgan RA, Blaese RM.

J Virol. 1998 Mar;72(3):1769-74.

42.

Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency.

Onodera M, Ariga T, Kawamura N, Kobayashi I, Ohtsu M, Yamada M, Tame A, Furuta H, Okano M, Matsumoto S, Kotani H, McGarrity GJ, Blaese RM, Sakiyama Y.

Blood. 1998 Jan 1;91(1):30-6.

43.

Human gene marker/therapy clinical protocols.

Rosenberg SA, Blaese RM, Brenner MK, Deisseroth AB, Ledley FD, Lotze MT, Wilson JM, Nabel GJ, Cornetta K, Economou JS, Freeman SM, Riddell SR, Oldfield E, Gansbacher B, Dunbar C, Walker RE, Schuening FG, Roth JA, Crystal RG, Welsh MJ, Culver K, Heslop HE, Simons J, Wilmott RW, Boucher RC, et al.

Hum Gene Ther. 1997 Dec 10;8(18):2301-38. No abstract available.

PMID:
9449381
44.

Retrovirus-mediated gene transfer of ornithine-delta-aminotransferase into keratinocytes from gyrate atrophy patients.

Jensen TG, Sullivan DM, Morgan RA, Taichman LB, Nussenblatt RB, Blaese RM, Csaky KG.

Hum Gene Ther. 1997 Nov 20;8(17):2125-32.

PMID:
9414260
45.

Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells.

Ram Z, Culver KW, Oshiro EM, Viola JJ, DeVroom HL, Otto E, Long Z, Chiang Y, McGarrity GJ, Muul LM, Katz D, Blaese RM, Oldfield EH.

Nat Med. 1997 Dec;3(12):1354-61.

PMID:
9396605
46.

Structural and functional basis for JAK3-deficient severe combined immunodeficiency.

Candotti F, Oakes SA, Johnston JA, Giliani S, Schumacher RF, Mella P, Fiorini M, Ugazio AG, Badolato R, Notarangelo LD, Bozzi F, Macchi P, Strina D, Vezzoni P, Blaese RM, O'Shea JJ, Villa A.

Blood. 1997 Nov 15;90(10):3996-4003.

47.

Wiskott-Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype.

Zhu Q, Watanabe C, Liu T, Hollenbaugh D, Blaese RM, Kanner SB, Aruffo A, Ochs HD.

Blood. 1997 Oct 1;90(7):2680-9.

48.

Retroviral transfer of acid alpha-glucosidase cDNA to enzyme-deficient myoblasts results in phenotypic spread of the genotypic correction by both secretion and fusion.

Zaretsky JZ, Candotti F, Boerkoel C, Adams EM, Yewdell JW, Blaese RM, Plotz PH.

Hum Gene Ther. 1997 Sep 1;8(13):1555-63. Erratum in: Hum Gene Ther 1998 Apr 10;9(6):930.

PMID:
9322088
49.

A simple and reliable method for screening retroviral producer clones without selectable markers.

Onodera M, Yachie A, Nelson DM, Welchlin H, Morgan RA, Blaese RM.

Hum Gene Ther. 1997 Jul 1;8(10):1189-94.

PMID:
9215736
50.

Gene therapy for cancer.

Blaese RM.

Sci Am. 1997 Jun;276(6):111-5. No abstract available.

PMID:
9163943

Supplemental Content

Loading ...
Support Center